HTFLHealthcare · Health Information ServicesThe 9 Wall Street analysts covering HeartFlow, Inc. hold a median 12-month price target of $37 — +38.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores HeartFlow, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (83): Analysts have, on balance, been raising their forecasts.
Volatility (2): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own HeartFlow, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on HTFL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +38.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 July 2026 | Baird | Initiates | Outperform | $34 |
| 1 July 2026 | Freedom Capital Markets | Initiates | Buy | $37 |
| 1 July 2026 | Freedom Capital Markets | Initiates | Buy | — |
| 15 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 15 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 4 May 2026 | William Blair | Initiates | Outperform | — |
| 19 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 19 Mar 2026 | JP Morgan | Maintains | Overweight | — |
| 19 Mar 2026 | Wells Fargo | Maintains | Overweight | — |
| 9 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 28 Jan 2026 | Wells Fargo | Initiates | Overweight | — |
| 13 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 13 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 13 Nov 2025 | Stifel | Maintains | Buy | — |
| 22 Sept 2025 | Canaccord Genuity | Maintains | Buy | — |
| 2 Sept 2025 | Canaccord Genuity | Initiates | Buy | — |
| 2 Sept 2025 | JP Morgan | Initiates | Overweight | — |
| 2 Sept 2025 | Piper Sandler | Initiates | Overweight | — |
| 2 Sept 2025 | Stifel | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 92% of US stocks
Cheaper than 13% of US stocks
Cheaper than 13% of US stocks
Cheaper than 91% of US stocks
Higher than 84% of US stocks
Higher than 74% of US stocks
Higher than 91% of US stocks
Higher than 18% of US stocks
Higher than 9% of US stocks
Higher than 10% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HTFL appears on the weeks it earns a place.
A Benzinga article notes that Faeth Therapeutics received a bullish analyst initiation, listing it among top analyst initiations for the day. The excerpt does not mention HeartFlow, Inc. (HTFL) directly.
Why it matters — The article highlights analyst activity trends, which could indicate the kind of attention HTFL may receive in analyst coverage reports.
The 9 Wall Street analysts covering HeartFlow, Inc. have a median 12-month price target of $37, with estimates ranging from $34 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering HeartFlow, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HeartFlow, Inc. 27 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, HeartFlow, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (83 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +38.3% from the last close, and Ticker Nerd's factor model ranks HeartFlow, Inc. 27 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering HeartFlow, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HTFL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $40 over the next 12 months.
HeartFlow, Inc. is a medical technology company specializing in precision heart care through advanced AI-powered software solutions.
The most recent item we track (Benzinga, 31 July 2026): "This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday". A Benzinga article notes that Faeth Therapeutics received a bullish analyst initiation, listing it among top analyst initiations for the day. The excerpt does not mention HeartFlow, Inc. (HTFL) directly.
HeartFlow, Inc. is a medical technology company specializing in precision heart care through advanced AI-powered software solutions. It transforms coronary computed tomography angiography (CCTA) scans into detailed 3D models of patients' coronary arteries, enabling non-invasive assessment of coronary artery disease (CAD). Key products include Roadmap Analysis for efficient CAD detection, FFRCT Analysis to evaluate blood flow and revascularization needs, and Plaque Analysis to quantify and characterize plaque for risk assessment and disease management. The integrated HeartFlow One platform supports clinicians in identifying, deciding, and managing CAD, optimizing patient care pathways with personalized insights. HeartFlow also provides comprehensive support services, including clinical, operational, technical, and financial resources to help institutions build scalable CCTA programs. Headquartered in Redwood City, California, the company plays a pivotal role in advancing proactive, patient-centered coronary care by empowering healthcare providers with innovative tools to detect, understand, and treat CAD effectively.
CEO Mr. John C.M. Farquhar · 843 employees · United States · https://www.heartflow.com